Continuous glucose monitoring demonstrated 72% agreement with traditional fingerstick testing in 30 hospitalized seniors with both type 2 diabetes and cognitive impairment. The Dexcom G7 sensors showed a mean absolute relative difference of 17.4% compared to point-of-care tests, with 99.3% of readings falling within clinically acceptable ranges. Notably, CGM detected more nighttime hypoglycemic episodes that routine testing missed. This validation addresses a critical healthcare gap, as cognitive impairment affects glucose management by causing patients to forget blood sugar checks or miss symptom recognition. The technology could transform diabetes care in vulnerable hospitalized populations where traditional monitoring fails. Current hospital protocols rely heavily on intermittent fingerstick tests, which may miss dangerous glucose fluctuations, particularly during sleep when staff monitoring is reduced. The strong correlation (R²=0.82) between CGM and standard testing suggests these devices could safely replace more burdensome monitoring methods. However, this preprint awaits peer review, and the small sample size limits broader applicability. The finding represents an incremental but meaningful advance for geriatric diabetes management, potentially reducing hypoglycemic complications in cognitively impaired patients.